Literature DB >> 12163399

Apparent KIT Ser(715) deletion in GIST mRNA is not detectable in genomic DNA and represents a previously known splice variant of KIT transcript.

Jerzy Lasota, Janusz Kopczynski, Mourad Majidi, Markku Miettinen, Maarit Sarlomo-Rikala.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12163399      PMCID： PMC1850714          DOI： 10.1016/S0002-9440(10)64230-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  9 in total

1.  Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases.

Authors:  J Lasota; A Wozniak; M Sarlomo-Rikala; J Rys; R Kordek; A Nassar; L H Sobin; M Miettinen
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

Authors:  M L Lux; B P Rubin; T L Biase; C J Chen; T Maclure; G Demetri; S Xiao; S Singer; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

Authors:  B P Rubin; S Singer; C Tsao; A Duensing; M L Lux; R Ruiz; M K Hibbard; C J Chen; S Xiao; D A Tuveson; G D Demetri; C D Fletcher; J A Fletcher
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

4.  The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors.

Authors:  Johanna Andersson; Helene Sjögren; Jeanne M Meis-Kindblom; Göran Stenman; Pierre Aman; Lars-Gunnar Kindblom
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

5.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

6.  Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts.

Authors:  G Caruana; A C Cambareri; L K Ashman
Journal:  Oncogene       Date:  1999-09-30       Impact factor: 9.867

7.  Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia.

Authors:  P S Crosier; S T Ricciardi; L R Hall; M R Vitas; S C Clark; K E Crosier
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

8.  Expression of the Kit and KitA receptor isoforms in human acute myelogenous leukemia.

Authors:  X Piao; J E Curtis; S Minkin; M D Minden; A Bernstein
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113

9.  Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese.

Authors:  S Sakurai; S Oguni; M Hironaka; M Fukayama; S Morinaga; K Saito
Journal:  Jpn J Cancer Res       Date:  2001-05
  9 in total
  2 in total

1.  Repression of c-kit and its downstream substrates by GATA-1 inhibits cell proliferation during erythroid maturation.

Authors:  Veerendra Munugalavadla; Louis C Dore; Bai Lin Tan; Li Hong; Melanie Vishnu; Mitchell J Weiss; Reuben Kapur
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

2.  Phase II trial of imatinib mesylate in patients with metastatic melanoma.

Authors:  K B Kim; O Eton; D W Davis; M L Frazier; D J McConkey; A H Diwan; N E Papadopoulos; A Y Bedikian; L H Camacho; M I Ross; J N Cormier; J E Gershenwald; J E Lee; P F Mansfield; L A Billings; C S Ng; C Charnsangavej; M Bar-Eli; M M Johnson; A J Murgo; V G Prieto
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.